The UK Food Standards Agency (FSA) has published a list of the first CBD products that can remain on sale in the UK, with Cann Group’s Satipharm capsule range among those given the green light.
In January 2019, the novel food regulations were applied to CBD, requiring all suppliers to submit applications for authorisation by the FSA before they could be approved for sale.
The FSA has now published a list of the first products that are “one step closer to being authorised”, pending final rulings expected by mid-2023.
While those on the list can remain on sale while the final authorisation process takes place, the FSA stressed it did not mean any of the products have been endorsed.
Inclusion on the list also does not guarantee they will be authorised, FSA chief executive Emily Miles said.
Satipharm, which has been supplying its range of CBD capsules in the UK since 2016, submitted a dossier to the FSA in early 2020.
Cann Group said the move presents “a major opportunity” for the firm to grow sales as key UK retailers have been unable to range the products since 2019.
CEO Peter Crock added: “Over 800 product dossiers were submitted by various CBD manufacturers for review. Of these, the FSA has rejected over 600 which did not satisfy the validation criteria.
“The inclusion of the Satipharm products in the list demonstrates Cann’s real commitment to quality and consumer safety. We see this as a great opportunity to accelerate our sales in the UK.”